NASHVILLE, Tenn. & EMERYVILLE, Calif.–(BUSINESS WIRE)–PhaseOne Well being pronounces the growth of its industrial program for PhaseOne Pores and skin and Wound Care Cleanser via collaborative partnerships with revolutionary wound dressing producers and key wound and burn care specialists in the US. PhaseOne is formulated with NovaBay Prescription drugs’ (NYSE American: NBY) patented, steady hypochlorous acid.
“We count on wound care to be a bigger a part of our enterprise in 2023 and we’re excited to accomplice with PhaseOne Well being to develop our gross sales within the coming yr,” mentioned Justin Corridor, CEO of NovaBay Prescription drugs.
Kris Perkins, Managing Director of PhaseOne Well being, additional defined, “We’re constructing on triple-digit proportion development over the previous couple of years by aligning with key opinion leaders and advisors to increase our industrial packages in 2023. Combining our previous industrial success with current ends in new scientific functions positions us effectively to pursue synergistic enterprise and protocol growth with different firms and suppliers to deal with giant market alternatives not solely in wound care however in different surgical functions as effectively.”
PhaseOne is pure hypochlorous acid (HOCI), part of the physique’s pure immune system. HOCl is extensively generally known as protected and efficient for managing biofilm, micro organism, and fungi to advertise the therapeutic course of. Naturally produced by the physique’s white blood cells, HOCl was first synthesized by French scientist Antoine Jerome Balard in 1834 nevertheless its use in scientific functions has expanded vastly throughout the previous 10 years. Whereas PhaseOne is primarily used for pre- and post-plastic surgical procedure procedures, this coming yr will deliver an elevated focus within the wound care market.
PhaseOne differentiates itself within the wound care market by using NovaBay’s distinctive formulation of HOCI. Via its proprietary manufacturing course of and amber glass bottle, NovaBay ensures the most secure, purest, strongest HOCl wound cleanser available on the market. Its effectiveness is independently documented within the examine Comparative Antimicrobial Exercise of Industrial Wound Care Options on Bacterial and Fungal Biofilms (Harriott, PhD et al) printed within the peer-reviewed journal Annals of Plastic Surgical procedure.
“The Comparative Antimicrobial Exercise examine is exclusive and compelling due to the massive variety of bacterial species evaluated. Much more vital is the massive variety of bacterial and fungal strains evaluated inside every of those teams. This examine documented the efficacy of HOCI on the whole for penetrating biofilm and killing quite a few gram-negative and gram-positive micro organism in addition to fungi. It additionally confirmed that when hypochlorous acid is saved in UV-resistant glass, akin to Part One, in comparison with plastic, there’s a pattern for quicker motion in penetrating biofilm and killing related organisms. When dealing both with a surgical pocket or a wound, purity and velocity of motion usually tend to profit the scientific state of affairs,” mentioned Jack Fisher, MD, Chief Medical Officer of PhaseOne Well being. “Resulting from PhaseOne Well being’s current successes within the wound care market, we can be seeking to increase our efforts.”
Mr. Perkins added, “This yr we’re excited to concentrate on partnering with organizations dedicated to offering extra environment friendly, cost-effective therapeutic options and therapies for wound and burn sufferers. We may also proceed supporting impartial research that additional discover utilization of PhaseOne in different specializations like ladies’s well being. We’re wanting ahead to seeing PhaseOne Well being proceed to influence the wound care market and assist to heal these in want.”
About PhaseOne Well being and HOCl:
PhaseOne Well being hypochlorous acid safely penetrates biofilm. Biofilm represents a big barrier to wound therapeutic. PhaseOne (HOCl) answer is efficient at penetrating biofilm and mitigating its issues. PhaseOne is a broad spectrum non-toxic and non-irritating answer and doesn’t result in anti-microbial resistance.
Based mostly in Nashville, TN, PhaseOne Well being licenses, markets and distributes PhaseOne, a registered trademark of NovaBay Prescription drugs, Inc.
About NovaBay Prescription drugs, Inc.:
NovaBay Prescription drugs, Inc. develops and sells scientifically created and clinically confirmed eyecare and skincare merchandise. NovaBay’s main product, Avenova® Antimicrobial Lid & Lash Resolution, is commonly prescribed by eyecare professionals for blepharitis and dry-eye illness and can be accessible on to eyecare customers via on-line distribution channels akin to Amazon. DERMAdoctor® provides greater than 30 OTC dermatologist-developed skincare merchandise via the DERMAdoctor web site, well-known conventional and digital magnificence retailers, and worldwide distributors. NovaBay additionally manufactures and sells efficient, but mild and non-irritating wound care merchandise. The PhaseOne® model is distributed via industrial companions within the U.S. for skilled use solely, and the NeutroPhase® model is distributed in China by Pioneer Pharma (Hong Kong) Firm Ltd.
NovaBay Prescription drugs Ahead-Wanting Statements
Aside from historic info herein, issues set forth on this press launch could also be ahead wanting throughout the that means of the “protected harbor” provisions of the Non-public Securities Litigation Reform Act of 1995, together with statements concerning the industrial progress and future monetary efficiency of NovaBay Prescription drugs, Inc. This launch incorporates forward-looking statements which are primarily based upon administration’s present expectations, assumptions, estimates, projections and beliefs. These statements embody, however aren’t restricted to, statements concerning our enterprise methods, present partnerships, advertising and marketing efforts, and any future income which will end result from such partnerships and associated advertising and marketing initiatives, in addition to usually the Firm’s anticipated future monetary outcomes. These statements contain identified and unknown dangers, uncertainties and different elements which will trigger precise outcomes or achievements to be materially totally different and hostile from these expressed in or implied by the forward-looking statements. Components that may trigger or contribute to such variations embody, however aren’t restricted to, dangers and uncertainties regarding the scale of the potential marketplace for our merchandise, the chance that the accessible marketplace for the Firm’s merchandise won’t be as giant as anticipated, the Firm’s merchandise will be unable to penetrate a number of focused markets, and revenues won’t be adequate to fulfill the Firm’s money wants. Different dangers regarding NovaBay’s enterprise, together with dangers that would trigger outcomes to vary materially from these projected within the forward-looking statements on this press launch, are detailed in NovaBay’s newest Type 10-Q/Okay filings and Registration Assertion on Type S-1 submitting with the Securities and Alternate Fee, particularly underneath the heading “Danger Components.” The forward-looking statements on this launch converse solely as of this date, and NovaBay disclaims any intent or obligation to revise or replace publicly any forward-looking assertion besides as required by regulation.
